CPC A61K 31/7048 (2013.01) [A61K 31/4545 (2013.01); A61K 31/4706 (2013.01); A61K 31/4745 (2013.01); A61K 31/497 (2013.01); A61K 31/517 (2013.01); A61K 31/55 (2013.01); A61K 31/675 (2013.01); A61K 31/704 (2013.01); A61K 45/06 (2013.01)] | 7 Claims |
1. A method of treating lung cancer in an individual, comprising: administering to the individual a pharmaceutically effective amount of (a) a first active agent adapted for producing secretion of prostate apoptosis response-4 (Par-4) from normal cells and (b) a second active agent adapted for elevating GRP78 receptors for Par-4 on a surface of a cancer cell in the individual wherein the the first active agent is selected from a first group of agents consisting of chloroquine, hydroxychloroquine, etoposide, doxorubicin, Nutlin, irinotecan and combinations thereof and the second active agent is selected from a second group of agents consisting of crizotinib, brigatinib, lorlatinib, alectinib, sepantronium bromide (YM155), afatinib, gefitinib, erlotinib, osimertinib, alisertib, barasertib, danusertib, 1-Cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea (AT9283), N-(2-((1S,4R)-6-((4-(Cyclobutylamino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-1,2,3,4-tetrahydro-1,4-epiminonaphthalen-9- yl)-2- oxoethyl)acetamide (PF-03814735), N-[4-[3-(2-aminopyrimidin-4-yl)pyridin-2-yl]oxyphenyl]-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG900) and combinations thereof and the second active agent is administered at a dosage rate of 400 mg/day.
|